Cargando…
Belatacept in kidney transplant patients with systemic lupus erythematosus
OBJECTIVES: Lupus nephritis (LN) requires renal replacement therapy in 10%–30% of patients. About 30% of these patients receive a kidney transplant. Belatacept is a second-generation, selective, T-cell co-stimulator blocker (inhibits cytotoxic, T-lymphocyte antigen 4, CTLA-4) used as an alternative...
Autores principales: | Carrión-Barberà, Irene, Fajardo, Melissa, Danias, George, Tsapepas, Demetra, Gartshteyn, Yevgeniya, Fernandez, Hilda, Askanase, Anca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928461/ https://www.ncbi.nlm.nih.gov/pubmed/31908816 http://dx.doi.org/10.1136/lupus-2019-000355 |
Ejemplares similares
-
SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2021) -
Intermuscular adipose tissue in patients with systemic lupus erythematosus
por: Gamboa, Jorge Luis, et al.
Publicado: (2022) -
COVID-19 and systemic lupus erythematosus: a case series
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2020) -
Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus
por: Kapoor, Teja, et al.
Publicado: (2020) -
ECG non-specific ST-T and QTc abnormalities in patients with systemic lupus erythematosus compared with rheumatoid arthritis
por: Geraldino-Pardilla, Laura, et al.
Publicado: (2016)